Fig. 5

Effect of tofacitinib (Tofa), dosed (a) orally (PO; 0.3–30 mg/kg, with accompanying intracecal (IC) dosing of vehicle) or (b) IC (0.1–10 mg/kg, with accompanying PO dosing of vehicle), on oxazolone (Oxa)-induced pSTAT1 production in the mouse colon (mean ± SEM, n = 3–10). Each control mouse received both PO and IC vehicles. Corresponding colon and plasma concentrations of tofacitinib following (c) oral and (d) intracecal dosing are shown (individual data points and the mean value (±SEM); n = 4–9). ** p = 0.001 vs. Veh/Veh (Student’s t-test), ## p = 0.005–0.03, ### p = 0.0002–0.0005, and #### p < 0.0001 vs. Veh/Oxa (One-way ANOVA, Fisher’s LSD post-hoc test)